A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safet — ANTHONY O CAGGIANO (COGNITI
ABSTRACT. Soluble oligomers of beta amyloid (Aβ) protein are the most potent neuroactive structural form of this protein and evidence suggests they cause the synaptotoxic changes resulting in cognitiv
| Project title | A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safet |
|---|---|
| Project number | 3R01AG058660-03S1A1 |
| PI name | ANTHONY O CAGGIANO |
| Institution | COGNITION THERAPEUTICS, INC. |
| Funding mechanism | R01 |
| Agency | NIA |
| Award amount | $13.63M |
| Fiscal year | 2021 |
| Project start | 2018-09-15T00:00:00 |
| Project end | 2024-05-31T00:00:00 |
| Abstract | ABSTRACT. Soluble oligomers of beta amyloid (Aβ) protein are the most potent neuroactive structural form of this protein and evidence suggests they cause the synaptotoxic changes resulting in cognitiv |
| Key terms | <A β-42><A β42><A-beta 42><A-beta42><AD dementia><Abeta-42><Abeta42><Alzheimer><Alzheimer Type Demen |
$799/mo
Try GrantRadar →